Tags

Type your tag names separated by a space and hit enter

Post-approval safety issues with innovative drugs: a European cohort study.
Drug Saf. 2013 Nov; 36(11):1105-15.DS

Abstract

BACKGROUND

At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of approval is often even less extensive and these may require tighter scrutiny post approval.

OBJECTIVE

We evaluated whether more post-approval serious safety issues were identified for drugs with a higher level of innovation.

METHODS

A cohort study was performed that included all new active substances approved under the European Centralized Procedure and for which serious safety issues were identified post-approval from 1 January 1999 to 1 January 2012. Serious safety issues were defined as issues requiring a Direct Healthcare Professional Communication to alert individual healthcare professionals of a new serious safety issue, or a safety-related drug withdrawal. Data were retrieved from publicly available websites of the Dutch Medicines Evaluation Board and the European Medicines Agency. The level of innovation was scored using a validated algorithm, grading drugs as important (A), moderate (B) or modest (C) innovations or as pharmacological or technological (pharm/tech) innovations. The data were analyzed using appropriate descriptive statistics and Kaplan-Meier analysis, with a Mantel-Cox log-rank test, and Cox-regression models correcting for follow-up duration, to identify a possible trend in serious safety issues with an increasing level of innovation.

RESULTS

In Europe, 279 new drugs were approved between 1999 and 2011. Fifty-nine (21 %) were graded as important, 63 (23 %) moderate, or 34 (12 %) modest innovations and 123 (44 %) as non-innovative (pharm/tech), while 15 (25 %), 13 (21 %), 8 (24 %) and 17 (14 %) had post-approval safety issues, respectively (p = 0.06, linear-by-linear test). Five drugs were withdrawn from the market. The Kaplan-Meier-derived probability for having a first serious safety issue was statistically significant, log-rank (Mantel-Cox) p = 0.036. In the final adjusted Cox proportional hazard model there was no statistically significant difference in occurrence of a first serious safety issue for important, moderate and modest innovations versus non-innovative drugs; hazard ratios 1.76 (95 % CI 0.82-3.77), 1.61 (95 % CI 0.76-3.41)], and 1.25 (95 % CI 0.51-3.06), respectively.

CONCLUSION

A higher level of innovation was not clearly related to an increased risk of serious safety issues identified after approval.

Authors+Show Affiliations

Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, FB20, P.O. Box 196, 9700 AD, Groningen, The Netherlands, p.g.m.mol@umcg.nl.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24048690

Citation

Mol, Peter G M., et al. "Post-approval Safety Issues With Innovative Drugs: a European Cohort Study." Drug Safety, vol. 36, no. 11, 2013, pp. 1105-15.
Mol PG, Arnardottir AH, Motola D, et al. Post-approval safety issues with innovative drugs: a European cohort study. Drug Saf. 2013;36(11):1105-15.
Mol, P. G., Arnardottir, A. H., Motola, D., Vrijlandt, P. J., Duijnhoven, R. G., Haaijer-Ruskamp, F. M., de Graeff, P. A., Denig, P., & Straus, S. M. (2013). Post-approval safety issues with innovative drugs: a European cohort study. Drug Safety, 36(11), 1105-15. https://doi.org/10.1007/s40264-013-0094-y
Mol PG, et al. Post-approval Safety Issues With Innovative Drugs: a European Cohort Study. Drug Saf. 2013;36(11):1105-15. PubMed PMID: 24048690.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Post-approval safety issues with innovative drugs: a European cohort study. AU - Mol,Peter G M, AU - Arnardottir,Arna H, AU - Motola,Domenico, AU - Vrijlandt,Patrick J, AU - Duijnhoven,Ruben G, AU - Haaijer-Ruskamp,Flora M, AU - de Graeff,Pieter A, AU - Denig,Petra, AU - Straus,Sabine M J M, PY - 2013/9/20/entrez PY - 2013/9/21/pubmed PY - 2014/6/7/medline SP - 1105 EP - 15 JF - Drug safety JO - Drug Saf VL - 36 IS - 11 N2 - BACKGROUND: At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of approval is often even less extensive and these may require tighter scrutiny post approval. OBJECTIVE: We evaluated whether more post-approval serious safety issues were identified for drugs with a higher level of innovation. METHODS: A cohort study was performed that included all new active substances approved under the European Centralized Procedure and for which serious safety issues were identified post-approval from 1 January 1999 to 1 January 2012. Serious safety issues were defined as issues requiring a Direct Healthcare Professional Communication to alert individual healthcare professionals of a new serious safety issue, or a safety-related drug withdrawal. Data were retrieved from publicly available websites of the Dutch Medicines Evaluation Board and the European Medicines Agency. The level of innovation was scored using a validated algorithm, grading drugs as important (A), moderate (B) or modest (C) innovations or as pharmacological or technological (pharm/tech) innovations. The data were analyzed using appropriate descriptive statistics and Kaplan-Meier analysis, with a Mantel-Cox log-rank test, and Cox-regression models correcting for follow-up duration, to identify a possible trend in serious safety issues with an increasing level of innovation. RESULTS: In Europe, 279 new drugs were approved between 1999 and 2011. Fifty-nine (21 %) were graded as important, 63 (23 %) moderate, or 34 (12 %) modest innovations and 123 (44 %) as non-innovative (pharm/tech), while 15 (25 %), 13 (21 %), 8 (24 %) and 17 (14 %) had post-approval safety issues, respectively (p = 0.06, linear-by-linear test). Five drugs were withdrawn from the market. The Kaplan-Meier-derived probability for having a first serious safety issue was statistically significant, log-rank (Mantel-Cox) p = 0.036. In the final adjusted Cox proportional hazard model there was no statistically significant difference in occurrence of a first serious safety issue for important, moderate and modest innovations versus non-innovative drugs; hazard ratios 1.76 (95 % CI 0.82-3.77), 1.61 (95 % CI 0.76-3.41)], and 1.25 (95 % CI 0.51-3.06), respectively. CONCLUSION: A higher level of innovation was not clearly related to an increased risk of serious safety issues identified after approval. SN - 1179-1942 UR - https://www.unboundmedicine.com/medline/citation/24048690/Post_approval_safety_issues_with_innovative_drugs:_a_European_cohort_study_ L2 - https://dx.doi.org/10.1007/s40264-013-0094-y DB - PRIME DP - Unbound Medicine ER -